Teva/Ivax closing date extended
Executive Summary
The closing date for Teva's acquisition of Ivax has been extended, Teva announces Jan. 10; the consent order for the acquisition is still under review by the Federal Trade Commission, company reports. The two generics firms "have no reason to believe that the acceptance will not be forthcoming shortly, and expect to close the merger later this month." Teva announced the $7.4 bil. acquisition in July 2005 (1"The Pink Sheet" Aug. 1, 2005, p. 19)...
You may also be interested in...
Teva/Ivax Merger Will Create Significant Pricing Flexibility In Generics
Teva is prepared to leverage its $7.4 bil. acquisition of Ivax to offer the lowest prices on generic drugs "if need be," Ivax Chairman Phillip Frost said July 26 during a call regarding the deal
There’s ‘No Silver Bullet’ For Making Medicines Packaging Sustainable
There’s no simple answer to the question of how to make medicines packaging sustainable, says international recycling consultancy and Veolia Group subsidiary Circpack. “Manufacturers need to assess what works best for them, and recyclers will do the same,” Circpack analyst and circular packaging expert Filipe Vieira de Castro tells HBW Insight in this exclusive Q&A. “The best thing we can all do is put effort into finding common ground between systems, which comes down to better understanding the complexities between them.”
Entries Begin To Roll In For 2024 Industry Awards
Entries have now begun rolling in for the Global Generics & Biosimilars Awards, which returns to Milan this October, Free to enter and attend, the ceremony recognizes the top achievements across the generics, biosimilars and value added medicines industries.